ரோபோ உலகளாவிய News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ரோபோ உலகளாவிய. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ரோபோ உலகளாவிய Today - Breaking & Trending Today
Private markets: Biotech funds point to the future Healthcare has had a year like no other for at least two reasons. The first is obvious. The second is all about investment. In April, for example, healthcare ETFs saw their highest level of inflows – $7.3 billion at the global level. And although this amounted to just $0.5 billion in Europe, even that was a regional record. BlackRock, which published the numbers, said the interest in medical device production and in pharmaceutical innovation had offered investors two rationales for investing in the sector. At Goldman Sachs Asset Management (GSAM), Luke Barrs – a portfolio management leader – said that the pandemic had “supercharged an existing secular trend and pushed healthcare right to the top of governments’ and societies’ priorities”. He was speaking as GSAM launched a healthcare public equity fund. ....
Biotechnology – in the spotlight thanks to Covid-19 – surpasses even digital in terms of its scope to transform this century. Much of its funding comes from private equity, where investors face ethical as well as financial dilemmas. Alex Rolandi reports. ....
Biotechnology: Investing in cures With the Covid-19 pandemic, biotechnology and Big Pharma are back in the spotlight. Investors in life sciences are essentially backing developments that could determine the future of the human race, but what does investing in ‘cures’ mean from a cashflow point of view? The Genome Revolution, a 2018 Goldman Sachs report, states that “the potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy”. It goes on to say that “such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies”. Everybody ultimately wants to see cures for serious life-threatening illnesses, but the underlying science is not that easy, says David Pinniger, fund manager on investment firm Polar Capital’s healthcare team. ....